dpp-4 inhibitors vs. glp-1 agonist Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology Dipeptidyl Peptidase (DPP)-IV Inhibitors with
Description
In addition to helping with weight loss, GLP-1s have been shown to support better overall wellness, including improved blood sugar control, lower risk of heart and kidney disease and relief from joint or sleep-related issues caused by excess weight
Therefore, considering the direct role of GIP and GLP-1 in adipose tissue, this effect on adipose tissue may also be beneficial in NAFLD
First, participants were asked about their experience with GLP-1 drugs (see Table 1)
Nutrition and Diabetes
CTL: cytotoxic T lymphocyte
As further GIP-GLP-1 receptor co-agonists were developed those findings were confirmed [51]
